Announcement • Nov 20
GB Sciences, Inc. announced delayed 10-Q filing On 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Feb 13
GB Sciences, Inc. announced delayed 10-Q filing On 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Nov 15
GB Sciences, Inc. announced delayed 10-Q filing On 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 15
GB Sciences, Inc. announced delayed 10-Q filing On 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jul 02
GB Sciences, Inc. announced delayed annual 10-K filing On 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Nov 15
GB Sciences, Inc. announced delayed 10-Q filing On 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Jul 12
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge Gb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents. Announcement • Jul 01
GB Sciences, Inc. announced delayed annual 10-K filing On 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Jan 20
GB Sciences, Inc., Annual General Meeting, Mar 09, 2023 GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof. Announcement • Jul 01
GB Sciences, Inc. announced delayed annual 10-K filing On 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Mar 30
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article Gb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors. Announcement • Mar 03
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis Gb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease. Announcement • Jan 13
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million. An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term.
An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021. Announcement • Sep 15
GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation Gb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients. Announcement • Jul 02
GB Sciences, Inc. announced delayed annual 10-K filing On 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Nov 26
GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of Directors GB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests. Announcement • Sep 19
Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX). Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level.
Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. Announcement • Aug 18
GB Sciences, Inc. announced delayed 10-Q filing On 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 14
GB Sciences, Inc. announced delayed annual 10-K filing On 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 